Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of Alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine

Journal of Alzheimer's Disease

Volumn 51, Issue 2, 2016, Pages 489-500

  Aso, Ester ^a,b   Andrés Benito, Pol ^a,b   Carmona, Margarita ^a,b   Maldonado, Rafael ^c   Ferrer, Isidre ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Alzheimer's disease; amyloid; A PP PS1 mice; cannabinoid receptor 2; cognitive impairment; tau; therapy; 9 tetrahidrocannabinol and cannabidiol

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; CANNABIDIOL; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR 2; CANNABIS; DRONABINOL; UNCLASSIFIED DRUG; CANNABINOID 2 RECEPTOR; CNR2 PROTEIN, MOUSE; MAPT PROTEIN, MOUSE; MEDICAL CANNABIS; NOOTROPIC AGENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXPERIMENTAL MODEL; FEMALE; MALE; MEDICINE; MOUSE; NEURITE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PROCESSING; THERAPY EFFECT; ANIMAL; BRAIN; C57BL MOUSE; COGNITION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MEMORY; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; TRANSGENIC MOUSE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CANNABIDIOL; COGNITION; DISEASE MODELS, ANIMAL; DRONABINOL; HUMANS; MALE; MEDICAL MARIJUANA; MEMORY; MICE, INBRED C57BL; MICE, TRANSGENIC; NOOTROPIC AGENTS; PRESENILIN-1; RANDOM ALLOCATION; RECEPTOR, CANNABINOID, CB2; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84961770701     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150913     Document Type: Article

References (37)

1. Cabral GA, Raborn ES, Griffin L, Dennis J, Marciano- Cabral F. (2008). CB2 receptors in the brain: Role in central immune function. Br J Pharmacol 153, 240-251.
2. Benito C, Tolón RM, Pazos MR, N'uñez E, Castillo AI, Romero J. (2010). Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 153, 277-285.
3. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
4. Viscomi MT, Oddi S, Latini L, Pasquariello N, Florenzano F, Bernardi G, Molinari M, MaccarroneM(2009). Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29, 4564-4570.
5. Atwood BK, MackieK(2010). CB2: Acannabinoid receptor with an identity crisis. Br J Pharmacol 160, 467-479.
6. Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, Casadó V, Lanciego JL, Franco R, Lluis C, Canela EI, McCormick PJ. (2012). Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem 287, 20851-20865.
7. Zhang HY, Gao M, Liu QR, Bi GH, Li X, Yang HJ, Gardner EL, Wu J, Xi ZX. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A 111, E5007-E5015.
8. Dhopeshwarkar A, Mackie K. (2014). CB2 Cannabinoid receptors as a therapeutic target-what does the future hold'. Mol Pharmacol 86, 430-437.
9. Ferrer I. (2012). Defining Alzheimer as acommonage-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol 97, 38-51.
10. Selkoe DJ. (2012). Preventing Alzheimer's disease. Science 337, 1488-1492.
11. Benito C, N'Uñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, Romero J. (2003). Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-Associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141.
12. Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, De Ceballos ML. (2005). Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913.
13. Solas M, Francis PT, Franco R, Ramírez MJ. (2013). CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. Neurobiol Aging 34, 805-808.
14. Savonenko AV, Melnikova T, Wang Y, Ravert H, Gao Y, Koppel J, Lee D, Pletnikova O, Cho E, Sayyida N, Hiatt A, Troncoso J, Davies P, Dannals RF, Pomper MG, Horti AG. (2015). Cannabinoid CB2 receptors in a mouse model of A- amyloidosis: Immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One 10, e0129618.
15. Tolón RM, N'Uñez E, Pazos MR, Benito C, Castillo AI, Martínez-Orgado JA, Romero J. (2009). The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-Amyloid removal by human macrophages. Brain Res 1283, 148-154.
16. Martín-Moreno AM, Brera B, Spuch C, Carro E, García- García L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, De Ceballos ML. (2012). Prolonged oral cannabinoid administration prevents neuroinflammation, lowers -Amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 9, 8.
17. Wu J, Bie B, Yang H, Xu JJ, Brown DL, Naguib M. (2013). Activation of the CB2 receptor system reverses amyloidinduced memory deficiency. Neurobiol Aging 34, 791-804.
18. Van Der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, Micale V, Steardo L, Drago F, Iuvone T, Di Marzo V. (2006). Endocannabinoids and beta-Amyloidinduced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63, 1410-1424.
19. Esposito G, Iuvone T, Savani C, Scuderi C, De Filippis D, Papa M, Di Marzo V, Steardo L. (2007). Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: In vitro and in vivo evidence. J Pharmacol Exp Ther 322, 1144-1152.
20. Fakhfouri G, Ahmadiani A, Rahimian R, Grolla AA, Moradi F, Haeri A. (2012). WIN55212-2 attenuates amyloid-betainduced neuroinflammation in rats through activation of cannabinoid receptors and PPAR- pathway. Neuropharmacology 63, 653-666.
21. Aso E, Juvés S, Maldonado R, Ferrer I. (2013). CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A-PP/PS1 mice. J Alzheimers Dis 35, 847-858.
22. Koppel J, VingtdeuxV, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P. (2014). CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. Mol Med 20, 29-36.
23. Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I. (2015). Cannabis-based medicine reduces multiple pathological processes inA-PP/PS1 mice. J Alzheimers Dis 43, 977-991.
24. Casarejos MJ, Perucho J, Gómez A, MuñozMP, Fernández- Estévez M, Sagredo O, Fernández-Ruiz J, Guzmán M, De Yébenes JG, Mena M.A. (2013). Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35, 525-539.
25. Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N, Cai J. (2014). The potential therapeutic effects of THC on Alzheimer's disease. J Alzheimers Dis 42, 973-984.
26. Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, De Ceballos ML. (2011). Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Mol Pharmacol 79, 964-973.
27. Cheng D, Low JK, Logge W, Garner B, Karl T. (2014). Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1-E9 mice. Psychopharmacology. (Berl). 231, 3009-3017.
28. Cheng D, Spiro AS, Jenner AM, Garner B, Karl T. (2014). Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice. J Alzheimers Dis 42, 1383-1396.
29. Huestis M.A. (2005). Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 168, 657-690.
30. Pertwee RG. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9- tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153, 199-215.
31. Russo EB. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163, 1344-1364.
32. Borchelt DR, Ratovitski T, Van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945.
33. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer A. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2). receptor. Eur J Pharmacol 396, 141-149.
34. Aso E, Palomer E, Juvés S, Maldonado R, Muñoz FJ, Ferrer I. (2012). CB1 agonist ACEA protects neurons and reduces the cognitive impairment of A-PP/PS1 mice. J Alzheimers Dis 30, 439-459.
35. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ. (2011). Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A 108, 5819-5824.
36. García-Gutiérrez MS, Ortega-A' lvaro A, Busquets-García A, Pérez-Ortiz JM, Caltana L, Ricatti MJ, Brusco A, Maldonado R, Manzanares J. (2013). Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 73, 388-396.
37. Schmole AC, Lundt R, Ternes S, Albayram Ö, Ulas T, Schultze JL, Bano D, Nicotera P, Alferink J, Zimmer A. (2015). Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model. Neurobiol Aging 36, 710-719.